Navidea Biopharmaceuticals (NAVB) Short Interest Ratio & Short Volume $0.0005 0.00 (0.00%) As of 08/7/2025 10:25 AM Eastern Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsOptions ChainSEC FilingsShort InterestTrendsBuy This Stock Navidea Biopharmaceuticals Short Interest DataNavidea Biopharmaceuticals (NAVB) has a short interest of 400 shares. This marks a 0.00% change in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 7,996 shares to cover all short positions.Current Short Interest400 sharesPrevious Short Interest400 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$0.08Short Interest Ratio0.0 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares100,080,000 sharesPercentage of Shares Shorted0.00%Today's Trading Volume1,768 sharesAverage Trading Volume7,996 sharesToday's Volume Vs. Average22% Short Selling Navidea Biopharmaceuticals? Sign up to receive the latest short interest report for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNAVB Short Interest Over TimeNAVB Days to Cover Over TimeNAVB Percentage of Float Shorted Over Time Navidea Biopharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/2025400 shares $0.08 No ChangeN/A0 $0.00 6/30/2025400 shares $0.40 No Change0.0%0.1 $0.00 6/15/2025400 shares $0.28 No Change0.0%0.1 $0.00 5/31/2025400 shares $0.28 No Change0.0%0.4 $0.00 5/15/2025400 shares $0.28 +33.3%N/A0.4 $0.00 4/30/2025300 shares $0.18 -25.0%N/A0 $0.00 4/15/2025400 shares $0.24 No ChangeN/A0.1 $0.00 3/14/2025400 shares $0.04 No ChangeN/A0.2 $0.00 2/14/2025400 shares $0.28 No ChangeN/A0 $0.00 1/31/2025400 shares $0.40 No ChangeN/A0.1 $0.00 Get the Latest News and Ratings for NAVB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/2025400 shares $0.04 No ChangeN/A0 $0.00 6/15/2023570,200 shares $51.32 thousand -35.3%4.5%0.1 $0.09 5/31/2023881,100 shares $81.06 thousand +1,888.9%3.7%0.4 $0.09 5/15/202344,300 shares $0.00 -92.5%0.2%0.1 $0.00 4/30/2023592,800 shares $0.00 +28.7%2.7%4.1 $0.00 4/15/2023460,700 shares $133.05 thousand -7.0%2.1%3.8 $0.29 3/31/2023495,500 shares $0.00 +6.3%2.3%3.7 $0.00 3/15/2023466,100 shares $0.00 +4.2%2.2%3.1 $0.00 2/28/2023447,300 shares $0.00 +2.0%2.1%3 $0.00 2/15/2023438,500 shares $0.00 +38.2%2.1%2.9 $0.00 1/31/2023317,300 shares $0.00 +660.9%1.5%2.3 $0.00 1/15/202341,700 shares $0.00 +118.3%0.2%0.4 $0.00 12/30/202219,100 shares $0.00 -83.7%0.1%0.2 $0.00 12/15/2022117,200 shares $0.00 -12.5%0.5%1.7 $0.00 11/30/2022133,900 shares $0.00 +27.5%0.6%1.3 $0.00 11/15/2022105,000 shares $0.00 -8.2%0.5%0.8 $0.00 10/31/2022114,400 shares $0.00 -50.2%0.5%0.7 $0.00 10/15/2022229,900 shares $0.00 -50.7%1.1%1.4 $0.00 9/30/2022466,700 shares $0.00 +20.2%2.2%3 $0.00 9/15/2022388,300 shares $0.00 +60.3%1.8%2.6 $0.00 8/31/2022242,300 shares $0.00 +319.9%1.1%2.3 $0.00 8/15/202257,700 shares $0.00 -2.9%0.3%0.9 $0.00 7/31/202259,400 shares $0.00 -38.1%0.3%1.4 $0.00 7/15/202296,000 shares $0.00 -5.0%0.4%1.9 $0.00 6/30/2022101,000 shares $0.00 +45.3%0.5%0.3 $0.00 6/15/202269,500 shares $0.00 -16.3%N/A0.2 $0.00 5/31/202283,000 shares $0.00 +2.1%0.4%0.2 $0.00 5/15/202281,300 shares $0.00 -63.6%0.4%0.2 $0.00 4/30/2022223,300 shares $0.00 +121.5%1.0%0.6 $0.00 4/15/2022100,800 shares $0.00 -1.0%0.5%0.3 $0.00Altucher: Trump’s Great Gain is starting (Ad)New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.See Altucher’s Trump crypto prediction here 3/31/2022101,800 shares $0.00 -33.4%0.5%1.6 $0.00 3/15/2022152,800 shares $0.00 -15.9%0.7%2.1 $0.00 2/28/2022181,600 shares $0.00 -7.6%0.8%2.2 $0.00 2/15/2022196,500 shares $0.00 -12.4%0.9%2.3 $0.00 1/31/2022224,400 shares $0.00 -1.4%1.0%2.4 $0.00 1/15/2022227,500 shares $0.00 +1.9%1.1%3.3 $0.00 12/31/2021223,200 shares $0.00 +63.9%1.0%3.1 $0.00 12/15/2021136,200 shares $0.00 -7.1%0.6%2.1 $0.00 11/30/2021146,600 shares $0.00 +4.1%0.7%2.3 $0.00 11/15/2021140,900 shares $0.00 -10.8%0.6%2.4 $0.00 10/29/2021157,900 shares $0.00 -9.3%0.7%2.9 $0.00 10/15/2021174,100 shares $0.00 -7.0%0.8%4 $0.00 9/30/2021187,200 shares $0.00 +13.8%0.9%3 $0.00 9/15/2021164,500 shares $0.00 -5.4%0.8%2.5 $0.00 8/31/2021173,800 shares $0.00 +9.3%0.8%2.4 $0.00 8/13/2021159,000 shares $0.00 -17.0%0.7%1.4 $0.00 7/30/2021191,500 shares $0.00 -4.3%0.9%1.5 $0.00 7/15/2021200,000 shares $0.00 -1.6%1.0%1.4 $0.00 6/30/2021203,200 shares $0.00 +12.3%1.0%1.4 $0.00 6/15/2021181,000 shares $0.00 +30.2%0.9%0.9 $0.00 5/28/2021139,000 shares $0.00 -23.4%0.7%0.7 $0.00 5/14/2021181,500 shares $0.00 +5.5%N/A0.8 $0.00 4/30/2021172,000 shares $0.00 -7.2%N/A0.6 $0.00 4/15/2021185,300 shares $290.92 thousand -15.5%N/A0.5 $1.57 3/31/2021219,400 shares $355.43 thousand +49.3%N/A0.6 $1.62 3/15/2021147,000 shares $255.78 thousand -22.3%N/A0.4 $1.74 2/26/2021189,200 shares $389.75 thousand +13.8%N/A0.6 $2.06 2/12/2021166,200 shares $402.20 thousand -33.0%N/A0.5 $2.42 1/29/2021248,100 shares $615.29 thousand -8.4%N/A0.6 $2.48 1/15/2021270,800 shares $785.32 thousand -2.9%N/A0.9 $2.90 12/31/2020279,000 shares $558 thousand -1.6%N/A1.1 $2.00 12/15/2020283,500 shares $532.98 thousand +9.0%N/A1.2 $1.88 11/30/2020260,000 shares $624 thousand +32.9%N/A1.1 $2.40 11/15/2020195,600 shares $539.86 thousand +3.4%N/A0.8 $2.76 10/30/2020189,100 shares $457.62 thousand -3.3%N/A1.1 $2.42 10/15/2020195,600 shares $535.94 thousand -11.1%N/A0.8 $2.74 9/30/2020220,100 shares $594.27 thousand +11.4%N/A0.7 $2.70 9/15/2020197,500 shares $582.63 thousand -12.7%1.1%0.6 $2.95 8/31/2020226,100 shares $671.52 thousand +5.0%1.3%0.5 $2.97 8/14/2020215,300 shares $704.03 thousand -5.2%1.3%0.3 $3.27 NAVB Short Interest - Frequently Asked Questions What is Navidea Biopharmaceuticals' current short interest? Short interest is the volume of Navidea Biopharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of July 15th, traders have sold 400 shares of NAVB short. Learn More on Navidea Biopharmaceuticals' current short interest. How does Navidea Biopharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Navidea Biopharmaceuticals: Vincerx Pharma, Inc. (0.02%), Orgenesis Inc. (0.17%), Smart for Life, Inc. (0.01%), Syros Pharmaceuticals, Inc. (0.40%), Virpax Pharmaceuticals, Inc. (1.24%), Scopus BioPharma Inc. (0.02%), Evelo Biosciences, Inc. (0.04%), Comera Life Sciences Holdings, Inc. (0.01%), Genocea Biosciences, Inc. (0.33%), Aridis Pharmaceuticals, Inc. (0.04%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Navidea Biopharmaceuticals stock? Short selling NAVB is an investing strategy that aims to generate trading profit from Navidea Biopharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Navidea Biopharmaceuticals? A short squeeze for Navidea Biopharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NAVB, which in turn drives the price of the stock up even further. How often is Navidea Biopharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NAVB, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies VINC Short Interest ORGS Short Interest SMFL Short Interest SYRS Short Interest VRPX Short Interest SCPS Short Interest EVLO Short Interest CMRA Short Interest GNCAQ Short Interest ARDS Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSE:NAVB) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
